Table 1.
Baseline characteristics of subjects in the SET and the control group
| Characteristics | Total patients (n=41)
|
P-value | |
|---|---|---|---|
| SET (n=27) | Control (n=14) | ||
| Sex M/F, n (%) | 12:15 (44.4:55.6) | 7:7 (50.0:55.0) | 0.735 |
| Age (years) | 71.9±6.4 | 72.0±7.9 | 0.858 |
| Smoking (pack-years) | 36.5±23.4 | 32.8±20.3 | 0.923 |
| BMI (kg/m2) | 19.3±4.3 | 20.3±3.8 | 0.316 |
| Exacerbations in 12 months before trial (n) | 2.1±1.7 | 3.6±1.7 | 0.649 |
| COPD admissions in 12 months before trial (n) | 1.9±1.1 | 2.4±1.1 | 0.439 |
| FEV1 (% predicted) | 40.1±12.8 | 44.2±16.7 | 0.573 |
| FEV1/FVC (%) | 55.2±14.3 | 54.2±10.8 | 0.869 |
| COPD GOLD Stage III–IV | 18 (66.7) | 8 (57.1) | 0.511 |
| SaO2 (%) | 92.7±4.9 | 91.7±5.6 | 0.330 |
| PaO2 (mmHg) | 71.4±14.4 | 67.2±10.8 | 0.328 |
| Hct (%) | 46.2±6.4 | 44.3±9.0 | 0.606 |
| 6-MWD (m) | 227.1±86.4 | 231.1±114.8 | 0.880 |
| SGRQ score | 55.5±21.0 | 61.4±10.8 | 0.752 |
| mMRC score | 2.4±1.2 | 2.2±0.8 | 0.518 |
| BDI score | 5.1±2.8 | 4.5±2.2 | 0.739 |
| MIP (cmH2O) | 47.8±24.6 | 49.9±23.8 | 0.967 |
| Upper limb strength (Watt) | 49.3±23.6 | 53.2±24.8 | 0.489 |
| Lower limb strength (Watt) | 55.3±27.0 | 58.8±19.0 | 0.619 |
| Inhaled medications n (%) | |||
| LAAC | 8 (29.6) | 4 (28.6) | 0.864 |
| ICS + LABA | 4 (14.8) | 3 (21.4) | |
| ICS + LABA + LAAC | 15 (55.6) | 7 (50.0) | |
Note: Data are n (%) or mean ± standard deviation.
Abbreviations: SET, Suandok exercise training; M, male; F, female; BMI, body mass index; COPD, chronic obstructive pulmonary disease; FEV1 (% predicted), percentage predicted of forced expiratory volume in first second; FEV1/FVC, ratio of FEV1 to FVC; FVC, forced vital capacity; GOLD, Global initiative for chronic Obstructive Lung Disease; SaO2, oxygen saturation; PaO2, partial pressure of oxygen in arterial blood; Hct, hematocrits; 6-MWD, 6-minute walk distance; SGRQ, St George’s Respiratory Questionnaire; mMRC, modified Medical Research Council; BDI, baseline dyspnea index; MIP, maximal inspiratory pressure; LAAC, long-acting anticholinergics; ICS, inhaled corticosteroids; LABA, long-acting beta2-agonists.